Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Human immunoglobulin G (IgG) heavy chain hinge region is a specialized, flexible amino acid sequence located between the CH1 and CH2 constant domains of the IgG heavy chain [1]. Its primary biological function is to provide the Fab arms with the necessary mobility to bind bivalently to antigens at varying distances and orientations [2]. Structurally, the hinge region contains the inter-chain disulfide bridges that covalently link the two heavy chains, maintaining the overall Y-shaped architecture of the antibody [1]. In clinical medicine, this region is a critical target for Imlifidase (IdeS), a cysteine protease that specifically cleaves the IgG hinge to separate the Fab fragments from the Fc region [3]. This cleavage effectively abolishes the antibody's ability to trigger complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) [4]. Consequently, the IgG hinge region is a focal point for therapeutic intervention in antibody-mediated rejection during organ transplantation and in severe autoimmune diseases [3, 5]. Citations: [1] UniProt Consortium, P01857; [2] Roux, K. H., et al. (1997) J Immunol; [3] Jordan, S. C., et al. (2017) N Engl J Med; [4] Hansson, S., et al. (2020) Curr Opin Organ Transplant; [5] Lonze, B. E., et al. (2018) Am J Transplant.
Proteolytic cleavage of the hinge region at a specific amino acid sequence (e.g., Gly-Pro-Ser-Val-Phe-Leu-Phe) to separate the antigen-binding Fab fragments from the effector-mediating Fc fragment, thereby neutralizing antibody effector functions [3, 4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human immunoglobulin G heavy chain hinge region (IgG hinge).